|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thyroid tissue blocks from 42 consecutive pediatric WDTC patients who underwent thyroidectomy between 2001 and 2013 were analyzed at Quest Diagnostics for BRAF(V600E), RAS mutations (N,K,H), and RET/PTC and PAX8/PPARγ rearrangements, using validated molecular methods.
|
26649796 |
2016 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activation of the ret proto-oncogene by three different chromosomal rearrangements occurs in up to 25% of papillary thyroid carcinomas.
|
7491517 |
1995 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated whether a specific type of RET/PTC rearrangement was induced by X-rays in vivo and in vitro.
|
10656692 |
2000 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CCI = Charlson Comorbidity Index; CCR = California Cancer Registry; CI = confidence interval; DTC = differentiated thyroid cancer; FTC = follicular thyroid carcinoma; HCC = Hürthle cell carcinoma; IQR = interquartile range; mPTC = papillary thyroid micro-carcinoma; OR = odds ratio; OSPHD = Office of Statewide Health Planning and Development; PTC = papillary thyroid carcinoma.
|
28816539 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Methylation-specific PCR analyses showed that SLC5A8 was methylated in 90% of PTC-cf. and in about 20% of other papillary thyroid carcinomas.
|
15687339 |
2005 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that some variants of RET and some specific haplotypes may act as low penetrance alleles in the predisposition to PTC.
|
11950855 |
2002 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The constitutive activation of the RET by somatic rearrangement with other partner genes or germ-line mutations causes a considerable population of human papillary thyroid carcinomas or multiple endocrine neoplasia (MEN) type 2A and 2B, respectively, whereas the dysfunction of RET by germ-line missense and/or nonsense mutations causes Hirschsprung's disease.
|
15013219 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CLN = central lymph node; PTC = papillary thyroid carcinoma; PTMC = papillary thyroid microcarcinoma.
|
30289307 |
2018 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The RET/PTC band was weaker or absent in pure LT areas.
|
11747322 |
2001 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We found a significant association between the localization of RET mutations and the expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid cancer).
|
28181547 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rearranged during transfection (RET)/papillary thyroid carcinoma (PTC) gene rearrangements are one of the major genetic alterations found in papillary thyroid carcinoma.
|
24957039 |
2014 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, RET/PTC rearrangements and BRAF mutations were associated with the different clinical and histopathological features in pediatric PTC.
|
31085772 |
2019 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally the orientation of RET on chromosome 10q11.2 made it possible to orientate three other genes rearranged with RET in papillary thyroid carcinomas, namely H4/D10S170 on 10q21, R1 alpha on 17q23 and RFG2/Ele1 on 10q11.2.
|
7478601 |
1995 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Comparing the cytological or, when performed, histological diagnoses with the results of FNAB-Tg, we found that in 24 cases of lymph node metastases from PTC (19 lymph nodes from patients at the first diagnoses and 5 lymph nodes from PTC patients in follow up) the mean level of Thyroglobulin was 1840.11 ng/ml; range: <0,2 to 11440 ng/ml.
|
28558632 |
2017 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
|
15184868 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In particular, the frequency of RET/PTC rearrangements decreased from 1996-2010, occurring in 33 of 100 (33%) of the patients in group 1, 26 of 148 (17%) in group 2, and 15 of 153 (9.8%) in group 3.
|
22745248 |
2012 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results, together with data from our previous studies on RAS, RET rearrangements and NTRK1 rearrangements in the same tumours, were compared to determine their individual significance in the pathogenesis of PTCs in Taiwan.
|
16181240 |
2005 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that BRAF mutation and RET/PTC rearrangements are molecular markers of PTC that can be applied to FNA in adjunct to traditional cytology.
|
15472223 |
2004 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
|
1437145 |
1992 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our data reveal that both multiplex qPCR and FISH assays are equally applicable for detection of RET/PTC rearrangements.
|
25407564 |
2015 |
|
Papillary thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most frequent genetic alterations described thus far in human papillary thyroid carcinomas are somatic rearrangements of the RET proto-oncogene, which generate the chimeric RET/PTC oncogenes.
|
9438393 |
1998 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using human thyroid cancer-derived cell lines [harboring rearranged during transfection (RET)/PTC, v-RAF murine sarcoma viral oncogene homolog B (BRAF), or rat sarcoma virus oncogene (RAS) alterations], we determined that IL-6/gp130/JAK signaling is responsible for STAT3 activation.
|
22891351 |
2012 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Due to lack of tissue specimen harboring the rare RET chimeras, artificially constructed hybrid sequences of all known RET/PTC variants served as PCR controls.
|
17655865 |
2007 |
|
Papillary thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RET/PTC expression and BRAF mutations were mutually exclusive.
|
16402937 |
2006 |